IBM Stock Falls 1.5% as Mainframe Slump Overshadows Quantum Progress

Key Takeaways

• IBM shares fell 1.46% to $233.69 on 20 August, ending a two-session advance and leaving the stock almost 30% below its June record high.
• Weak second-quarter results remain the main concern: IBM Z revenue dropped 42%, infrastructure revenue fell 7%, and the company reduced its 2026 revenue-growth outlook.
• Quantum computing progress, government software opportunities and wider European distribution have not yet outweighed earnings uncertainty, legal scrutiny and lower analyst targets.

IBM shares declined on Thursday as investors remained cautious about the technology group’s mainframe slowdown and the credibility of its post-earnings recovery plan. The stock closed 1.46% lower at $233.69, ending a two-day winning streak and remaining 29.7% below its 52-week high of $332.46, reached on 2 June.

The move did not occur during a broad market rebound. The S&P 500 fell 0.87%, while the Dow Jones Industrial Average lost 1.32%. IBM nevertheless underperformed several large technology peers. Volume was subdued at roughly 4 million shares, compared with a 50-day average near 10 million, suggesting persistent caution rather than panic selling.

IBM’s Q2 Mainframe Slump Remains the Central Concern

The pressure on IBM stock can still be traced to July’s sharp earnings reset. IBM initially released disappointing preliminary figures on 14 July, triggering a one-day decline of more than 20%. Its final second-quarter report confirmed that revenue rose only 1% year on year to $17.16 billion, while adjusted earnings were $2.93 per share. Both figures fell short of market expectations.

The segment breakdown exposed a particularly weak quarter for IBM’s infrastructure business. IBM’s Q2 results showed infrastructure revenue falling 7% to $3.8 billion. Hybrid infrastructure declined 10%, and IBM Z mainframe revenue dropped 42%. Distributed infrastructure offered one bright spot with 37% growth, but it was not enough to offset the mainframe contraction.

Software revenue increased 5% to $7.76 billion, while consulting revenue was broadly flat at $5.33 billion. IBM’s software transition was therefore not strong enough to offset the hardware downturn.

IBM also lowered its full-year revenue-growth forecast to 4%–5% at constant currency, from an earlier expectation of more than 5%. Management maintained its forecast for free cash flow to increase by around $1 billion from 2025, but investors now need evidence that delayed transactions are converting into recognised revenue.

The company has argued that some large deals slipped out of the quarter rather than disappearing, with several closing early in Q3. This distinction matters because IBM Z installations can also generate software, maintenance, financing and consulting revenue. A timing problem could support a second-half recovery; a lasting demand decline would create wider pressure across the mainframe ecosystem.

Shareholder-Law-Firm Investigations Add Headline Risk

The post-earnings sell-off has also attracted legal scrutiny. Bleichmar Fonti & Auld and other shareholder law firms are reviewing whether IBM made misleading statements about the pace of large-deal closures and the strength of the IBM Z outlook before the July decline. BFA’s notice describes an investigation into potential securities claims.

This is not a regulatory finding, court judgment or proof that IBM committed fraud. Nevertheless, the reviews create headline risk. Investors will watch whether they develop into formal litigation or produce information that challenges IBM’s explanation of the Q2 shortfall.

Quantum, Maximo and Arrow Expansion Offer Positive Offsets

IBM has continued to announce progress outside its mainframe business. On 19 August, it said it had connected and cooled two modular cryogenic units within one environment. The design is intended to help link hundreds of quantum chips and advance fault-tolerant computing. The official announcement supports IBM’s technology story, but is unlikely to change near-term earnings by itself.

IBM’s Maximo Application Suite for Government has also received FedRAMP Moderate authorisation. The approval, published by IBM in April, gives US agencies a compliant cloud option for managing critical assets. Contract awards will determine its financial impact.

Arrow Electronics has meanwhile expanded its IBM distribution coverage to Bulgaria, Croatia, the Czech Republic, Germany, Slovakia, Slovenia and Ukraine. The seven-country expansion broadens access to IBM infrastructure, automation, data and software products through European channel partners.

These developments support IBM’s longer-term story, but investors currently appear to be assigning more weight to revenue, margins and cash flow.

Analyst Target Cuts Reflect Lower Confidence, Not a Uniformly Bearish View

Several firms reduced their IBM targets after the Q2 warning. Susquehanna cut its target to $225 from $303 while retaining a Neutral rating. Argus lowered its target to $280 from $360 but kept a Buy rating. Citigroup first cut its target to $255 from $375 and later to $245, while maintaining a Buy rating.

WallStreetZen also moved IBM from Hold to Sell in July, adding to the negative headlines, although its rating should be distinguished from the recommendations issued by major investment banks.

The overall picture remains mixed rather than outright bearish. A MarketBeat survey of 28 analysts shows a Moderate Buy consensus and an average 12-month target of $265.40, with estimates ranging from $175 to $350. The average implies roughly 14% upside from Thursday’s close, but the wide range illustrates high uncertainty.

What Could Move IBM Stock Next?

IBM shares are likely to remain sensitive to evidence that Q2’s delayed deals have closed and that software growth can offset the mainframe downturn. A convincing Q3 improvement, stable free-cash-flow guidance and stronger IBM Z orders could help rebuild confidence. Further guidance reductions, weak transaction-processing software demand or an escalation of legal claims could renew selling pressure.

From a price-action perspective, the area around $230 is an immediate reference point, followed by the July low near $212. On the upside, the mid-$240s may act as the first resistance zone, with the $255–$265 region aligning with several revised analyst targets. Until IBM provides clearer evidence of an operational rebound, positive quantum and government-software news may remain secondary to the company’s earnings execution.